Sterling Biotech Limited announced unaudited standalone earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net sales/income from operations was INR 1,168.957 million against INR 1,843.581 million a year ago. Loss from operations before other income and finance costs was INR 488.072 million against INR 260.935 million a year ago. Loss from ordinary activities after finance costs but before tax was INR 1,309.776 million against INR 1,536.105 million a year ago. Net loss was INR 884.776 million against INR 1,037.705 million a year ago. Diluted loss per share before and after extraordinary items was INR 2.04 against INR 2.40 a year ago.

For the six months, the company reported net sales/income from operations was INR 2,175.256 million against INR 3,725.717 million a year ago. Loss from operations before other income and finance costs was INR 1,061.492 million against INR 532.421 million a year ago. Loss from ordinary activities after finance costs but before tax was INR 2,647.132 million against INR 3,065.701 million a year ago. Net loss was INR 1,788.232 million against INR 2,071.001 million a year ago. Diluted loss per share before and after extraordinary items was INR 4.13 against INR 4.78 a year ago.